EUCTR2013-000212-22-RO进行中（未招募）不适用
A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder
GW Research Ltd0 个研究点目标入组 78 人开始时间: 2014年5月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Participant is willing and able to give written informed consent for participation in the study and does not require involuntary treatment.
- •-Male or female participant(s) aged 18 to 65 years.
- •-Participant is able (in the investigator’s opinion) and willing to comply with all study requirements.
- •-Participant is diagnosed with schizophrenia or a related psychotic disorder (such as schizoaffective or schizophreniform disorder) as defined by the Diagnostic and Statistical Manual of Mental Disorders Version 4.
- •-Participant must have been treated for a minimum of four-weeks and be on a stable dose of their current AP medication.
- •-Participant must have shown the capacity to respond at least partially to first line AP medication in the opinion of the investigator.
- •-Participant must be able to remain stable on their dose of AP and concomitant medications for the duration of the study, in the opinion of the investigator.
- •-Participant is willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable in individual countries.
- •-Participant is willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 78
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Products (IMPs).
- •-Participant has a PANSS Total score of < 60 at Visit 1.
- •-Participant presents with a current clinical picture and/or history that is consistent with:
- •?delirium or dementia
- •?acute drug induced psychosis
- •?bipolar disorder
- •-Participant is taking more the one AP medication during the study.
- •-Female participants of child bearing potential and male participants whose partner is of child bearing potential, unless willing to ensure that they or their partner use effective contraception, for example, oral contraception, double barrier, intra-uterine device, during the study and for three months thereafter (however a male condom should not be used in conjunction with a female condom).
- •-Female participant who is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.
- •-Participants who have received an IMP within 30 days prior to the screening visit.
- •-Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
- •-Following a physical examination, the participant has any abnormalities that, in the opinion of the investigator would prevent the participant from safe participation in the study.
- •-Unwilling to abstain from donation of blood during the study.
- •-Travel outside the country of residence planned during the study.
- •-Participants previously randomised into this study.
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenic purpura.Immune thrombocytopenic purpura (ITP)EUCTR2004-000367-98-ESGlaxoSmithKline Research and Development Limited
进行中（未招募）
不适用
GWP42003 as adjunctive therapy to first line antipsychotics in schizophrenia and related psychotic disordersEUCTR2013-000212-22-PLGW Research Ltd78
进行中（未招募）
1 期
DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents (DINAMO)Diabetes Mellitus Type 2MedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2016-000669-21-PTnilfarma - União Internacional de Lab. Farmacêuticos, Lda.301
进行中（未招募）
1 期
A double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of SB-742457, donepezil and placebo on cognition in subjects with mild to moderate Alzheimer's DiseaseAlzheimer's diseaseEUCTR2006-000468-95-GBGlaxoSmithKline Research & Development Ltd
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of SB-742457, donepezil and placebo on cognition in subjects with mild to moderate Alzheimer's DiseaseAlzheimer's diseaseEUCTR2006-000468-95-DEGlaxoSmithKline Research & Development Ltd200